Literature DB >> 26935356

Pupillary Reconstruction and Outcome after Artificial Iris Implantation.

Christian S Mayer1, Lukas Reznicek2, Andrea E Hoffmann2.   

Abstract

PURPOSE: Patients with iris defects suffer from severe visual impairment, especially increased glare sensitivity and cosmetic disturbances. This constitutes a great psychological strain for those patients. Until recently, possible treatment options were iris print contact lenses, sunglasses, and simple iris prostheses. The aim of this study was to investigate structural and functional outcome parameters and patient satisfaction after implantation of this new artificial iris prosthesis.
DESIGN: Prospective case series investigating functional results and patient satisfaction after surgical iris reconstruction. PARTICIPANTS: Thirty-seven consecutive patients with traumatic iris defects presenting from 2011 through 2014 underwent pupillary reconstruction with a new artificial iris implant at the Department of Ophthalmology, Technical University Munich.
METHODS: The custom-made, flexible silicone iris prosthesis ArtificialIris (HumanOptics, Erlangen, Germany) used in this study is a novel and innovative device in the surgical treatment of iris defects. Patients were examined before and after iris reconstruction with the iris implant placed in the ciliary sulcus. MAIN OUTCOME MEASURES: Change of best-corrected visual acuity (BCVA), intraocular pressure (IOP), pupillary aperture, glare, contrast sensitivity, endothelial cell density, anterior chamber depth, anterior chamber angle, and patient satisfaction were assessed.
RESULTS: Thirty-two eyes of 32 patients (mean age, 52.9±16.0 years) were included. After implantation and during follow-up, BCVA and IOP did not change significantly (BCVA, 0.77±0.62 logarithm of the minimum angle of resolution [logMAR] preoperatively vs. 0.68±0.64 logMAR 1 month postoperatively [P = 0.792]; IOP, 14.94±3.55 mmHg preoperatively vs. 17.72±5.88 mmHg 1 month postoperatively [P = 0.197]). The pupillary aperture was reduced significantly (42.11±20.1 mm(2) to 8.7±0.3 mm(2); P < 0.001). Contrast sensitivity increased significantly (0.80±0.51 to 0.93±0.49; P = 0.014). Endothelial cell count revealed a significant decrease postoperatively (1949±716 per 1 mm(2) to 1841±689 per 1 mm(2); P = 0.003). Anterior chamber depth (4.03±1.06 mm preoperatively vs. 4.29±0.70 mm postoperatively; P = 0.186) and angle (43.2±13.5° preoperatively vs. 40.5±10.8° postoperatively; P = 0.772) showed no significant differences. Subjective impairment through glare (9.12±1.62 preoperatively vs. 3.07±2.29 postoperatively; P < 0.001) and cosmetic disturbance (6.33±3.21 preoperatively vs. 1.58±0.86 postoperatively; P < 0.001) improved significantly. Patient satisfaction with the overall result was 8.91±1.51 of 10 points on an analog scale.
CONCLUSIONS: The implantation of the artificial iris is a new and effective therapeutic option for the treatment of distinctive traumatic iris defects and results in an individual, aesthetically appealing, and good functional outcome in addition to high patient satisfaction.
Copyright © 2016 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26935356     DOI: 10.1016/j.ophtha.2016.01.026

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  21 in total

1.  [Postoperative maximum dilated fixed pupil and primary graft insufficiency after penetrating keratoplasty].

Authors:  G Schießl; T Hager; B Seitz
Journal:  Ophthalmologe       Date:  2018-01       Impact factor: 1.059

2.  Bilateral Artificial Iris implantation in patients with bilateral iris defects.

Authors:  Christian Steffen Mayer; Isabella Diana Baur; Julia Storr; Ramin Khoramnia
Journal:  Am J Ophthalmol Case Rep       Date:  2021-04-30

3.  Implantation of ArtificialIris, a CustomFlex irisprosthesis, in a trauma patient with an Artisan lens: A case report and review.

Authors:  Farideh Doroodgar; Mahmoud Jabbarvand; Feizollah Niazi; Sana Niazi; Azad Sanginabadi
Journal:  Medicine (Baltimore)       Date:  2017-11       Impact factor: 1.817

4.  Iris reconstruction using autologous iris preserved in cold balanced salt solution for 8 hours in iatrogenic total iridodialysis during cataract surgery: a case report.

Authors:  Seung Pil Bang; Jong Hwa Jun
Journal:  BMC Ophthalmol       Date:  2017-04-04       Impact factor: 2.209

5.  Bilateral BrightOcular iris implants necessitating explantation and subsequent endothelial keratoplasty.

Authors:  Zale Mednick; Devin Betsch; Tanguy Boutin; Adi Einan-Lifshitz; Nir Sorkin; Allan Slomovic
Journal:  Am J Ophthalmol Case Rep       Date:  2018-07-18

6.  [Bilateral explantation of iris implants due to pigment dispersion syndrome (PDS) and corneal decompensation after cosmetic iris implantation (BrightOcular)].

Authors:  Kleopatra Varna-Tigka; Franziska Löffler; Thomas Kohnen
Journal:  Ophthalmologe       Date:  2020-11       Impact factor: 1.059

7.  Functional outcomes after combined iris and intraocular lens implantation in various iris and lens defects.

Authors:  Christian S Mayer; Andrea M Hoffmann; Phillipp Prahs; Lukas Reznicek; Ramin Khoramnia
Journal:  BMC Ophthalmol       Date:  2020-09-15       Impact factor: 2.209

8.  Aesthetics of iris reconstruction with a custom-made artificial iris prosthesis.

Authors:  Timur M Yildirim; Ramin Khoramnia; Michael Masyk; Hyeck-Soo Son; Gerd U Auffarth; Christian S Mayer
Journal:  PLoS One       Date:  2020-08-13       Impact factor: 3.240

9.  Challenges and Complication Management in Novel Artificial Iris Implantation.

Authors:  Christian S Mayer; Andrea E Laubichler; Ramin Khoramnia; Tamer Tandogan; Philipp Prahs; Daniel Zapp; Lukas Reznicek
Journal:  J Ophthalmol       Date:  2018-09-23       Impact factor: 1.909

10.  Implantation of a small-aperture intraocular lens and a partial aniridia implant in eyes with traumatic iris defects.

Authors:  Hyeck-Soo Son; Timur Yildirim; Ramin Khoramnia; Grzegorz Labuz; Christian Mayer; Gerd U Auffarth
Journal:  Am J Ophthalmol Case Rep       Date:  2020-03-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.